C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 239/46 (2006.01) A61K 31/505 (2006.01) C07D 239/47 (2006.01)
Patent
CA 2625563
The present invention is directed to the dihydrogen phosphate salt of 2-(3-{6- [2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2- methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).
La présente invention concerne le sel dihydrogène phosphate de l'acide 2-(3-{6-[2-(2,4-dichloro-phényl)-éthylamino]-2-méthoxy-pyrimidin-4-yl}-phényl)-2-méthyl-propionique de formule (III), une composition pharmaceutique comprenant une quantité pharmaceutiquement efficace du composé de formule (III), et un support pharmaceutiquement acceptable. Elle concerne une méthode de traitement d'un patient souffrant d'un trouble induit par PGD2 tel que, mais pas exclusivement, une maladie allergique (rhinite allergique, conjonctivite allergique, dermatite atopique, asthme, allergie alimentaire), une mastocytose systémique, des troubles accompagnés d'une action systémique des mastocytes, le choc anaphylactique, la bronchoconstriction, la bronchite, l'urticaire, l'eczéma, les maladies accompagnées de grattage (telles que la dermatite atopique et l'urticaire), les affections telles que le cataracte, le décollement rétinien, l'inflammation, l'infection ou les troubles du sommeil résultant secondairement d'un comportement accompagné de grattage (grattage ou battage), l'inflammation, les bronchopneumopathies chroniques obstructives, la lésion consécutive à la perfusion ischémique, l'accident vasculaire cérébral, l'arthrite rhumatoïde chronique, la pleurésie, la colite ulcéreuse et analogues. Le traitement s'effectue par administration au patient d'une quantité pharmaceutiquement efficace du composé de formule (III).
Langevin Beverly
Orton Edward
Sherer Daniel
Aventis Pharmaceuticals Inc.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Dihydrogen phosphate salt of a prostaglandin d2 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydrogen phosphate salt of a prostaglandin d2 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydrogen phosphate salt of a prostaglandin d2 receptor... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1528833